The takeaway
Fennec Pharmaceuticals Inc shows a pronounced seasonal pattern over 10 years of data — strongest in September (+8.3%) and softest in October (−0.1%).
Right now
In July, the stock has risen 60% of years, averaging +2.6% — essentially in line with the S&P 500.
The full picture
Fennec Pharmaceuticals Inc's most dependable month has been September, higher in 7 of 10 years; October has been its least reliable, up just 40% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in September (+8.5 pts); it has trailed the market most in March (−2.5 pts).
“vs S&P” is Fennec Pharmaceuticals Inc’s average for a month minus the S&P 500’s average for that same month — isolating Fennec Pharmaceuticals Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, September has closed higher 60% of the time versus 70% across the last 10 years — the pattern is holding.
Figures are the typical (median) September return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a stock you can almost set a calendar by, and September is the anchor — it has closed higher in 7 of 10 Septembers, the steadiest beat on its year.
The strength looks broad-based rather than freakish: its average (+8.3%) and median (+7.0%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even September ranges by 18.7% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — September has outpaced the S&P 500 by +8.5 points on average. It is the more striking for the company it keeps — September is a losing month for most of the market, where barely 39% of names gain ground.
It doesn't stand entirely alone — January, February, and July have leaned firm as well, if less emphatically. At the other end of the calendar, October is the year's quietest corner, essentially flat on average, and the edge isn't year-round — the stock has trailed the S&P 500 in March, August, and October. Its roughest month on record was a −53.7% November in 2021 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
For a stock this dependable in September, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (September), its worst (October), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (September, +8.3%) has run well ahead of its worst (October, −0.1%) — the heatmap above shows how steady that gap has been year to year.
September has been the strongest, averaging +8.3% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −0.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade